Adaptimmune Therapeutics plc

8-K Delisting notice or listing-rule failure; Regulation FD disclosure Oct 20, 2025 8-K Delisting notice or listing-rule failure Sep 26, 2025 8-K Delisting notice or listing-rule failure Sep 12, 2025 8-K Director or officer change Sep 8, 2025 8-K Director or officer change Aug 29, 2025 8-K Director or officer change Aug 15, 2025 8-K Delisting notice or listing-rule failure Aug 14, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release) Aug 13, 2025 8-K Director or officer change Aug 7, 2025 8-K Terminated a material agreement; Completed an acquisition or disposition Jul 31, 2025 8-K Entered a material agreement; Exit or disposal costs; Director or officer change; Regulation FD disclosure Jul 28, 2025 8-K Other events Jul 17, 2025 8-K Shareholder vote results May 29, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 8-K Delisting notice or listing-rule failure May 1, 2025 8-K Director or officer change Apr 14, 2025 10-K Fiscal year ended 2024-12-31 Mar 24, 2025 8-K Entered a material agreement Mar 24, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 20, 2025 8-K Director or officer change; Other events Dec 19, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release); Exit or disposal costs Nov 13, 2024 8-K Other events Nov 13, 2024 8-K Delisting notice or listing-rule failure Nov 1, 2024 8-K Entered a material agreement Sep 23, 2024 10-Q Quarter ended 2024-06-30 Aug 12, 2024 8-K Results of operations (earnings release) Aug 12, 2024 8-K Regulation FD disclosure; Other events Aug 2, 2024 8-K Director or officer change Jul 16, 2024 8-K Director or officer change Jun 11, 2024 8-K Entered a material agreement; Regulation FD disclosure May 30, 2024 10-Q Quarter ended 2024-03-31 May 15, 2024 8-K Results of operations (earnings release) May 15, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Regulation FD disclosure May 15, 2024 8-K Shareholder vote results May 14, 2024 8-K Terminated a material agreement Apr 12, 2024 10-K Fiscal year ended 2023-12-31 Mar 6, 2024 8-K Results of operations (earnings release) Mar 6, 2024